Posted by Michael Wonder on 30 Sep 2020
Health Canada approves Reblozyl (luspatercept), new class of treatment for adult patients living with beta thalassaemia
29 September 2020 - Reblozyl is the first and only erythroid maturation agent approved for use in Canada.
Bristol Myers Squibb Canada and Acceleron Pharma announced today that Health Canada has approved Reblozyl (luspatercept) for the treatment of adult patients with red blood cell transfusion-dependent anaemia associated with beta thalassaemia.
Health Canada’s approval of Reblozyl is based upon findings from the phase 3, double-blind, randomised, placebo-controlled BELIEVE trial, which compared treatment with Reblozyl and best supportive care to placebo and best supportive care in patients with anaemia associated with beta-thalassaemia requiring regular red blood cell transfusions.
